Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
Cancers|October 14, 2022
Biomarkers in Liquid Biopsies for Prediction of Early Liver Metastases in Pancreatic CancerAnne-Sophie Mehdorn, Timo Gemoll, Hauke Busch, et al.
Langenbeck'S Archives of Surgery|June 15, 2017
Survival outcome and prognostic factors after pancreatoduodenectomy for distal bile duct carcinoma: a retrospective multicenter studyEkaterina Petrova, Felix Rückert, Sebastian Zach, et al.
Anesthesia and Analgesia|February 9, 2024
Thoracic Epidural Analgesia Is Not Associated With Improved Survival After Pancreatic Surgery: Long-Term Follow-Up of the Randomized Controlled PAKMAN TrialRosa Klotz, Azaz Ahmed, Anja Tremmel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2025
Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 TrialRainer Fietkau, Michael Ghadimi, Robert Grützmann, et al.
Heliyon|July 6, 2023
Clinical characteristics and long-term outcomes following pancreatic injury - An international multicenter cohort studyLaura L Meijer, Yrjö Vaalavuo, Sara Regnér, et al.
Journal of Cancer Research and Clinical Oncology|March 31, 2025
Pain and overall quality of life in palliatively treated colorectal cancer patients 1 year after diagnosis- results from the EDIUM cohortSophie Klara Schellack, Clara Breidenbach, Christoph Kowalski, et al.
Science Advances|September 1, 2023
BRAF<sup>Δβ3-αC</sup> in-frame deletion mutants differ in their dimerization propensity, HSP90 dependence, and druggabilityManuel Lauinger, Daniel Christen, Rhena F U Klar, et al.
JAMA Surgery|May 28, 2020
Gastrointestinal Complications After Pancreatoduodenectomy With Epidural vs Patient-Controlled Intravenous Analgesia: A Randomized Clinical TrialRosa Klotz, Jan Larmann, Christina Klose, et al.
Signal Transduction and Targeted Therapy|January 16, 2026
Vertical RAS pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterationsPhilipp Hafner, Steffen J Keller, Xun Chen, et al.
The Lancet. Gastroenterology & Hepatology|May 19, 2025
Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multicentre, investigator-masked, enrichment design, phase 4 diagnostic studyUjjwal M Mahajan, Bettina Oehrle, Elisabetta Goni, et al.
Pageof 8